Pfizer – Page 2

Pfizer Cuts 11 R&D Programs amid Ongoing Revenue Declines and Cost Realignment Efforts

1 month ago talkbio0Tagged Cost Savings, COVID19 (disease), digital enablement, earnings, Pfizer, Q3, R&D, Revenue Decline, Seagen acquisition

Pfizer; R&D cuts; revenue decline; cost savings; Q3 2025 earnings; COVID-19 product sales; digital enablement; AI in R&D; Seagen acquisition

Novo Nordisk Ups Metsera Bid to $10 Billion to Top Pfizer’s Offer

1 month ago talkbio0Tagged Acquisition, contingent value right, Diabetes, M&A, Metsera, Novo Nordisk, Obesity, Pfizer

Novo Nordisk; Metsera; Pfizer; M&A; biotech acquisition; contingent value right; obesity drugs; diabetes treatments

Metsera Calls Pfizer’s Threats ‘Nonsense’ as Rift Between Companies Widens

1 month ago talkbio0Tagged Chancery, Delaware Court, drug acquisition, Litigation, Merger, Metsera, Novo Nordisk, Obesity, Pfizer, regulatory approval

Metsera; Pfizer; Novo Nordisk; merger dispute; litigation; obesity drug acquisition; regulatory approval; Delaware Court of Chancery

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

2 months ago talkbio0Tagged Acquisition, Antitrust, bidding war, Metsera, Novo Nordisk, Obesity, Pfizer, Twice a day, Unsolicited Adverse Event, Weight-Loss Agents

Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs

White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations

2 months ago talkbio0Tagged AstraZeneca, drug price, Electromechanical dissociation, Fertility Agents, Fertilization in Vitro, Glucagon-Like Peptide 1, Medicaid, Most-Favored-Nation, Pfizer, Pricing, serono, Trump administration, United States Food and Drug Administration, Voucher

most-favored nation pricing; fertility drugs; IVF; Trump administration; drug pricing; Medicaid; FDA vouchers; GLP-1; EMD Serono; Pfizer; AstraZeneca

AstraZeneca Reaches Drug Pricing Deal with White House, Becomes Second Pharma to Do So

2 months ago talkbio0Tagged AstraZeneca, drug discounts, drug price, Medicaid, most-favored-nation pricing, Pfizer, tariffs, TrumpRx, White House

AstraZeneca; White House; drug pricing; Medicaid; TrumpRx; most-favored-nation pricing; tariffs; Pfizer; drug discounts

Trump Administration and Pfizer Strike ‘Most Favored Nation’ Drug Price Deal

2 months ago talkbio0Tagged AmericasMedicines.com, Direct-to-Consumer, Drug Industry, drug price, Medicaid, Nation, Pfizer, PhRMA, Transplant Registry Unified Management Program, TrumpRx

Trump; Pfizer; most favored nation; drug prices; Medicaid; TrumpRx; direct-to-consumer; pharmaceutical industry; PhRMA; AmericasMedicines.com

Despite Government Shutdown, Companies Still Plan to Submit FDA Applications

2 months ago talkbio0Tagged AbbVie, amgen, Application procedure, biology (field), drug applications, funding lapse, Government, J&J, Myers Squibb, Pfizer, pharmaceutical delays, shutdown, United States Food and Drug Administration, user fees

FDA shutdown; new drug applications; biologic applications; user fees; pharmaceutical delays; government funding lapse; AbbVie; Amgen; Bristol Myers Squibb; J&J; Pfizer

Metsera’s New Obesity Data Raises Efficacy Profile, Key Side Effect Questions for Pfizer After Acquisition

3 months ago talkbio0Tagged aspects of adverse effects, Effectiveness, Glucagon-Like Peptide 1, MET-097i, Metsera, Obesity, Pfizer, Pfizer acquisition, Phase 2 trial, Weight Loss

Metsera; Pfizer; obesity drug; MET-097i; GLP-1; side effects; efficacy; Phase 2 trial; weight loss; Pfizer acquisition

Pfizer’s $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market

3 months ago talkbio0Tagged biotech acquisition, Glucagon-Like Peptide 1, late-stage clinical development, M&A, Metsera, Obesity, Pfizer, Pharma, pharmaceutical market, Weight Loss

Pfizer; Metsera; obesity drugs; weight loss; pharma M&A; GLP-1; biotech acquisition; pharmaceutical market; late-stage clinical development